Insmed ( (INSM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insmed shares came under pressure even as Wall Street turned more bullish on the company’s outlook. Trading was volatile after fresh analyst commentary highlighted how much future growth is already priced into the stock.
Morgan Stanley upgraded Insmed to Overweight and sharply lifted its price target to $212, pointing to deepening Brinsupri prescribing and rising physician confidence. The bank now forecasts $1.2 billion in U.S. sales by 2026, while other analysts have also nudged targets higher on the drug’s stronger-than-expected launch momentum.
More about Insmed
YTD Price Performance: -16.51%
Average Trading Volume: 2,488,797
Technical Sentiment Signal: Buy
Current Market Cap: $31.32B
For further insights into INSM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.